Agiliti announces financial results for third quarter 2021 and raises full year 2021 guidance
Minneapolis--(business wire)--agiliti inc. (nyse: agti) (“agiliti”), a nationwide provider of healthcare technology management and service solutions to the united states healthcare industry, today announced its financial results for the quarter ended september 30, 2021, and raised its full-year guidance for 2021. third quarter 2021 highlights revenue growth of 35 percent year-over-year to $262 million net income of $9.7 million, up $19.9 million from the prior year period, and diluted income per share of $0.07, up $0.17 per share from the prior year period adjusted ebitda1 growth of 46 percent year-over-year to $82 million, and adjusted diluted earnings per share of $0.23, up $0.10 per share from the prior year period total debt of $1,044.4 million; net debt1 of $920.7 million; net leverage ratio1 further reduced to 2.9x raised full year 2021 guidance with expected revenue of $1,010-1,020 million and adjusted ebitda of $300-310 million2 “our strong results from the quarter and our increased financial guidance for the year reflect the powerful fundamentals of our business” said tom leonard, chief executive officer. “agiliti’s nationwide maintenance and logistics infrastructure places us within the local community of the healthcare providers we serve each day. this same operations network is now supporting our recent acquisitions, with a unique and differentiated value proposition for our customers, delivered though our local service teams.” third quarter and year-to-date 2021 financial results total revenue for the three months ended september 30, 2021, was $262.4 million, representing a 34.8 percent increase from total revenue of $194.7 million for the same period of 2020. total revenue for the nine months ended september 30, 2021, was $748.2 million, representing a 33.8 percent increase from total revenue of $559.1 million for the same period of 2020. net income for the three months ended september 30, 2021, was $9.7 million compared to a net loss of $10.2 million for the same period of 2020. net income for the nine months ended september 30, 2021, was $14.0 million, representing a $36.0 million increase compared to a net loss of $22.0 million for the same period of 2020. adjusted ebitda for the three months ended september 30, 2021, was $81.9 million, a 46.2 percent increase from adjusted ebitda of $56.1 million for the same period of 2020. adjusted ebitda for the nine months ended september 30, 2021, was $245.8 million, a 51.6 percent increase from adjusted ebitda of $162.2 million for same period of 2020. subsequent events on october 1, 2021, agiliti completed its acquisition of sizewise rentals, inc., (“sizewise”), a manufacturer and distributor of specialty hospital beds, surfaces and patient handling equipment. the transaction was financed with a combination of cash on hand as well as an incremental $150m term loan b (fungible with the existing 0% libor floor tranche). the combination enables agiliti to broaden its portfolio and clinical expertise within the growing specialty equipment services market, expand its total addressable market opportunity and target meaningful growth and cost reduction synergies. 2021 financial outlook for the full year 2021, the company now expects revenue to be in the range of $1,010 million to $1,020 million, an increase from the prior range of $965 million to $980 million, representing growth of 31 to 32 percent. in addition, the company now expects adjusted ebitda to be in the range of $300 million to $310 million, an increase from the prior range of $280 million to $290 million, representing growth of 28 to 31 percent. finally, the company expects capital expenditures for 2021 to be in the range of $67 million to $72 million, an increase from the prior range of $65 million to $70 million. capex as a percentage of revenue is expected to remain in the range of 6 to 7 percent. conference call information agiliti will hold a conference call to discuss its 2021 third quarter results on tuesday, november 9, at 5 p.m. eastern time (4 p.m. central time). the conference call can be accessed live over the phone by dialing 1-877-300-8521 or for international callers, 1-412-317-6026. a replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. the passcode for the live call and the replay is 10160759. the replay will be available until november 16, 2021. interested investors and other parties may view a simultaneous webcast of the conference call by visiting the agiliti investor relations site at https://investors.agilitihealth.com. the webcast replay will be available for a limited time shortly following the call. about agiliti agiliti is an essential service provider to the u.s. healthcare industry with solutions that help support a more efficient, safe and sustainable healthcare delivery system. agiliti serves more than 9,000 national, regional and local acute care and alternate site providers across the u.s. for more than eight decades, agiliti has delivered medical equipment management and service solutions that help healthcare providers reduce costs, increase operating efficiencies and support optimal patient outcomes. forward-looking statements safe harbor statement under the private securities litigation reform act of 1995: agiliti inc., believes statements in this presentation looking forward in time, including preliminary results, involve risks and uncertainties. the following factors, among others, could adversely affect our business, operations and financial condition causing our actual results to differ materially from those expressed in any forward-looking statements: our history of net losses and substantial interest expense; our need for substantial cash to operate and expand our business as planned; our substantial outstanding debt and debt service obligations; restrictions imposed by the terms of our debt; a decrease in the number of patients our customers are serving; our ability to effect change in the manner in which health care providers traditionally procure medical equipment; the absence of long-term commitments with customers; our ability to renew contracts with group purchasing organizations and integrated delivery networks; changes in reimbursement rates and policies by third-party payors; the impact of health care reform initiatives; the impact of significant regulation of the health care industry and the need to comply with those regulations; the effect of prolonged negative changes in domestic and global economic conditions; difficulties or delays in our continued expansion into certain of our businesses/geographic markets and developments of new businesses/geographic markets; additional credit risks in increasing business with home care providers and nursing homes, impacts of equipment product recalls or obsolescence; increases in vendor costs that cannot be passed through to our customers; and other risk factors as detailed in our final prospectus filed with the securities and exchange commission (“sec”), on april 26, 2021, and our quarterly reports on form 10-q. 1 non-gaap measures. see further discussion below. 2 with regard to the non-gaap adjusted ebitda guidance provided above, a reconciliation to gaap net income has not been provided as the quantification of certain items included in the calculation of gaap net income cannot be calculated or predicted at this time without unreasonable efforts. for example, the non-gaap adjustment for stock-based compensation expense requires additional inputs such as number of shares granted and market price that are not currently ascertainable, and the non-gaap adjustment for certain reserves and expenses depends on the timing and magnitude of these expenses and cannot be accurately forecasted. for the same reasons, the company is unable to address the probable significance of the unavailable information, which could have a potentially unpredictable, and potentially significant, impact on its future gaap financial results. 2021 2020 2021 2020 262,424 194,721 748,212 559,121 158,990 120,115 444,346 359,239 103,434 74,606 303,866 199,882 75,052 71,732 225,334 180,838 28,382 2,874 78,532 19,044 — — 10,116 — 10,711 13,560 40,444 46,532 17,671 (10,686 ) 27,972 (27,488 ) 7,943 (573 ) 13,832 (5,678 ) 9,728 (10,113 ) 14,140 (21,810 ) 60 95 117 198 9,668 (10,208 ) 14,023 (22,008 ) 0.07 (0.10 ) 0.12 (0.22 ) 0.07 (0.10 ) 0.11 (0.22 ) 130,380,551 98,983,296 117,578,750 98,973,853 138,490,526 98,983,296 125,515,000 98,973,853 september 30, december 31, 2021 2020 123,713 206,505 200,779 154,625 29,092 27,062 14,847 14,175 368,431 402,367 301,189 285,723 140,138 112,646 (251,530 ) (183,953 ) 189,797 214,416 1,122,530 817,113 56,692 51,214 528,119 402,095 18,884 16,151 2,284,453 1,903,356 15,849 16,044 15,607 14,155 15,691 15,572 48,712 37,215 37,658 38,671 2,784 6,347 6,858 8,800 24,111 22,727 167,270 159,531 1,028,626 1,145,055 57,216 53,794 45,919 40,283 109,469 62,748 13 10 932,867 513,902 (54,469 ) (68,492 ) (2,581 ) (3,619 ) 875,830 441,801 123 144 875,953 441,945 2,284,453 1,903,356 2021 2020 14,140 (21,810 ) 78,249 72,955 63,482 54,536 4,542 8,231 7,716 — 1,121 1,336 2,539 458 10,127 7,657 (3,939 ) (852 ) 12,040 (5,967 ) (30,305 ) (37,618 ) 1,241 (5,534 ) (5,392 ) (6,431 ) 4,701 (1,138 ) (21,849 ) 33,903 138,413 99,726 (23,912 ) (22,806 ) (15,539 ) (15,465 ) 8,187 2,157 (450,198 ) (89,706 ) (481,462 ) (125,820 ) 35,000 249,500 (35,000 ) (283,000 ) 198,052 124,844 (326,770 ) (5,895 ) (6,721 ) (6,312 ) (229 ) (199 ) (748 ) — (138 ) (322 ) 380 — (926 ) (1,138 ) 401,441 — (4,084 ) — — (145 ) — (1,771 ) 260,257 75,562 (82,792 ) 49,468 206,505 — 123,713 49,468 40,991 41,279 2,647 1,007 use of non-gaap information this press release contains non-gaap measures, including ebitda, adjusted ebitda, adjusted eps and net leverage ratio. we use these internally as measures of operational performance and disclose them externally to assist analysts, investors and lenders in their comparisons of operational performance, valuation and debt capacity across companies with differing capital, tax and legal structures. we believe the investment community frequently uses these measures in the evaluation of similarly situated companies. adjusted ebitda is also used by the company as a factor to determine the total amount of incentive compensation to be awarded to executive officers and other employees. ebitda, adjusted ebitda, adjusted eps and net leverage ratio, however, are not measures of financial performance under accounting principles generally accepted in the united states of america (“gaap”) and should not be considered as alternatives to, or more meaningful than, net income as measures of operating performance or to cash flows from operating, investing or financing activities or as measures of liquidity. since ebitda, adjusted ebitda, adjusted eps and net leverage ratio are not measures determined in accordance with gaap and are thus susceptible to varying interpretations and calculations, these measures, as presented, may not be comparable to other similarly titled measures of other companies. ebitda and adjusted ebitda do not represent amounts of funds that are available for management’s discretionary use. ebitda and adjusted ebitda presented may not be the same as ebitda and adjusted ebitda calculations as defined in the first lien credit facilities. three months ended nine months ended september 30, september 30, 2021 2020 2021 2020 9,668 (10,208 ) 14,023 (22,008 ) 10,711 13,560 40,444 46,532 7,943 (573 ) 13,832 (5,678 ) 46,860 42,597 138,676 124,659 75,183 45,376 206,975 143,505 4,360 3,206 10,127 7,657 — (3,266 ) 7,626 (256 ) 2,189 1,137 6,440 1,699 197 9,600 4,542 9,600 — — 10,116 — 81,929 56,053 245,826 162,205 (1) management and other expenses represent (a) management fees and buyout termination fee under the advisory services agreement, which was terminated in connection with the initial public offering and (b) employee related non-recurring expenses. (2) transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the northfield acquisition for the nine months ended september 30, 2021. (3) loss on extinguishment of debt consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our second lien term loan and the write-off of the unamortized deferred financing costs related to the amendment of our revolving credit facility. 2021 2020 2021 2020 $ 9,668 $ (10,208 ) $ 14,023 $ (22,008 ) 21,497 17,558 60,427 51,702 4,360 3,206 10,127 7,657 - (3,266 ) 7,626 (256 ) 2,189 1,137 6,440 1,699 197 9,600 4,542 9,600 - - 10,116 - (6,724 ) (4,733 ) (20,452 ) (15,527 ) $ 31,187 $ 13,294 $ 92,849 $ 32,867 138,491 103,706 125,515 103,680 $ 0.23 $ 0.13 $ 0.74 $ 0.32 (1) management and other expenses represent (a) management fees and buyout termination fee under the advisory services agreement, which was terminated in connection with the initial public offering and (b) employee related non-recurring expenses. (2) transaction costs represent costs associated with potential and completed mergers and acquisitions and are primarily related to the northfield acquisition for the nine months ended september 30, 2021. (3) tax receivable agreement remeasurement represents the change in the fair value of the tax receivable agreement. (4) loss on extinguishment of debt consists of the write-off of the unamortized deferred financing costs and debt discount and an additional 1% redemption price related to the repayment of our second lien term loan and the write-off of the unamortized deferred financing costs related to the amendment of our revolving credit facility. (5) income tax benefit associated with pre-tax adjustments represents the tax benefit or provision associated with the reconciling items between net income (loss) and adjusted net income. to determine the aggregate tax effect of the reconciling items, we utilized statutory income tax rates ranging from 0% to 26%, depending upon the applicable jurisdictions of each adjustment. september 30, 2021 $ 1,035.4 26.1 (17.1 ) $ 1,044.4 (123.7 ) $ 920.7 $ 317.8
